BioMarin Says Phase 3 Study Of VOXZOGO In Hypochondroplasia Met Primary Endpoint With 2.33 cm/Year Improvement In Annualized Growth Velocity vs. Placebo At 52 Weeks; Says sNDA Submitted To FDA
Share
Why It Matters
BioMarin's new medicine for a bone-growth condition worked better than a fake medicine in testing, so they asked the FDA for permission to sell it. This is a good sign the company did its homework right, but we won't know if doctors and patients will actually use it until later.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.